


Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-20. (Canceled)

21. (Currently Amended) A pharmaceutical composition comprising a SMIP compound and an antigen, wherein the SMIP compound is a benzazole compound of formula (XXI):



XXI

wherein,

A is selected from the group consisting of -O-, -S-, -NH-, and -NR₈-;

W is selected from the group consisting of -CH₂-, -O-, -S-, -NH-, and -NR₈-;

R₇ is selected from the group consisting of carbocyclyl, unfused carbocyclylcarbocyclyl, substituted aryl, unsubstituted aryl, substituted heteroaryl, unsubstituted heteroaryl, substituted fused arylheteroaryl, unsubstituted fused arylheteroaryl, substituted unfused arylaryl and unsubstituted unfused arylaryl;

R₆ is selected from the group consisting of substituted or unsubstituted aryl, and heteroaryl; and,

_____R₈ is independently substituted or unsubstituted alkyl;
or a pharmaceutically acceptable salt, ester, or prodrug thereof;
~~and a pharmaceutically acceptable excipient;~~
wherein said composition elicits ~~[[and]]~~ an immune response in a subject.

22-23. (Canceled)

24. (Previously presented) The pharmaceutical composition of claim 21 wherein the antigen is associated with a disease selected from the group consisting of BCG, cholera, plague, typhoid, hepatitis B infection, influenza, inactivated polio, rabies, measles, mumps, rubella, oral polio, yellow fever, tetanus, diphtheria, hemophilus influenzae b, meningococcus infection, and pneumococcus infection.

25. (Canceled)

26. (Previously presented) The pharmaceutical composition according to claim 21 wherein the immune response is the cellular production of one or more cytokines.

27-29. (Canceled)

30. (Previously presented) The pharmaceutical composition of claim 21 wherein the SMIP compound is selected from the group consisting of:

N-methyl-4-[(2-{[2-(1-methylethyl)phenyl]amino}-1H-benzimidazol-5-yl)oxy]pyridine-2-carboxamide;

N-methyl-4-[[1-methyl-2-({3-[(trimethylsilyl)ethynyl]phenyl} amino)-1H-benzimidazol-5-yl]oxy]pyridine-2-carboxamide;

N-methyl-4-[(1-methyl-2-{[2-(phenylcarbonyl)phenyl]amino}-1H-benzimidazol-5-yl)oxy]pyridine-2-carboxamide;

4-({2-[(4-butylphenyl)amino]-1,3-benzothiazol-5-yl}oxy)-N-methylpyridine-2-carboxamide;

N-methyl-4-({1-methyl-2-[(6-pyrrolidin-1-ylpyridin-3-yl)amino]-1H-benzimidazol-5-yl}oxy)pyridine-2-carboxamide;

4-({2-[1,1'-bi(cyclohexyl)-2-ylamino]-1-methyl-1H-benzimidazol-5-yl}oxy)-N-methylpyridine-2-carboxamide;

4-({2-[(4-chlorophenyl)amino]-1-methyl-1H-benzimidazol-5-yl}oxy)-N-1,3-thiazol-2-ylpyridine-2-carboxamide;

4-[(1-methyl-2-{[2-(methyloxy)phenyl]amino}-1H-benzimidazol-5-yl)oxy]-N-[3-(methyloxy)propyl]pyridine-2-carboxamide; and,

4-({2-[(4-ethylphenyl)amino]-1,3-benzoxazol-5-yl}oxy)-N-methylpyridine-2-carboxamide.

31-35. (Canceled)

36. (Previously presented) The pharmaceutical composition of claim 21, wherein the antigen is associated with influenza.

37. (Previously presented) The pharmaceutical composition of claim 21, wherein the antigen comprises haemagglutinin and/or neuraminidase surface protein.

38. (Previously presented) The pharmaceutical composition according to any one of claims 21, 24, 26, 36, or 37, further comprising an adjuvant.

39. (Previously presented) The pharmaceutical composition of claim 38, wherein the adjuvant is MF59.